Merck claims first Phase III survival data in bladder cancer for Keytruda, while Bristol shows potential for immunotherapy combinations in bladder and head and neck cancers at the annual SITC meeting.
Sponsors of PD-1 inhibitors pushed further into new indications for monotherapy and combinations in bladder and head and neck cancers with data presentations at the Society for Immunotherapy of Cancer meeting.
Lung cancer represents the biggest market for PD-1 and PD-L1 inhibitors, and has dominated recent headlines, but other smaller markets...
The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.
Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.
In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.
IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?
Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.
Gilead’s Kite division presented Phase I data for its next-generation CAR-T therapy KITE-363 in patients with B-cell lymphomas.
EFPIA says reforms make the continent less attractive for innovative firms.
